TrialThe Lancet. Oncology2025

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.

Quisette P Janssen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.